Evidence map›Paper›PMID 37736420›Full record

ArticleApplied biosafety : journal of the American Biological Safety Association2023

An Industry Proposal for a Cell and Gene Therapy Safety Data Sheet.

Qirong Wu, Shana Elkind, Francine Preston, Michael Wachala, Erin Dunn, Sarah K White, Dirk Windhorst, Kimberly DiGiandomenico, Colin McGuire, Herbert Brok and 1 more

Abstract read
In one paragraph

Article in Applied biosafety : journal of the American Biological Safety Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qirong WuJanssen, Spring House, Pennsylvania, USA.
Shana ElkindRocket Pharmaceuticals, Inc., Cranbury, New Jersey, USA.
Francine PrestonJohnson & Johnson Services, Inc., Spring House, Pennsylvania, USA.
Michael Wachala2seventy bio, Cambridge, Massachusetts, USA.
Erin DunnFujifilm Diosynth Biotechnologies, College Station, Texas, USA.
Sarah K WhiteThermo Fisher Scientific, Waltham, Massachusetts, USA.
Dirk WindhorstSanofi Aventis Deutschland GmbH, Frankfurt, Germany.
Kimberly DiGiandomenicoAstraZeneca, Gaithersburg, Maryland, USA.
Colin McGuireFormally of Thermo Fisher Scientific, Waltham, Massachusetts, USA.
Herbert BrokLonza, Geleen, The Netherlands.
Rachel HodgesBioPhorum Operations Group Ltd., London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A safety data sheet (SDS) is an established hazard communication tool for chemicals, for which no comparable document exists in the biotherapeutics industry. As the cell and gene therapy (CGT) field expands, industry leaders have identified a growing need to address this gap in communication of the unique occupational health and safety risks posed by CGT materials and products. Methods: Following the sections of a traditional chemical SDS, information was modified by industry subject matter experts, relevant to CGT biological materials. This guide was developed based on assumptions of a maximum biosafety level 2, and any chemical components present in the material were excluded from the hazard classification. Results: The guide contains necessary information to conduct a workplace risk assessment and communicate the unique workplace hazards posed by potential exposures to the material. The target audience is intended to be entities handling and producing these materials, plus collaborators, contractors, or operations sites receiving and handling the CGT material. An example of a CGT SDS is provided in Table 1. Discussion: The CGT SDS provides industry with a best practice to address an existing gap in hazard communication for CGT. We expect that, as the field evolves, so may the contents. The CGT SDS can be used as a reference for other biological modalities in the field. Conclusions: This initial CGT SDS communicates workplace hazards and assesses the unique risks posed by these biological materials and can assist in creating exposure control plans specific to the workplace hazards.

Indexed as

biosafetycell and gene therapyEnvironmental Health & Safetyhazard communicationsafety data sheetWorkplace Hazard Assessment

Identifiers

PMID37736420
PMCPMC10510680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.